Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initiating therapy for Parkinson's disease

D E Silver1, S Ruggieri

  • 1Scripps Memorial Hospital, La Jolla, CA, USA.

Neurology
|June 20, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PM<sub>2.5</sub> elemental composition in indoor residential environments and co-exposure effects on respiratory health in an industrial area.

Environmental research·2022
Same author

Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.

Leukemia·2015
Same author

FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients.

Cell death & disease·2015
Same author

FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients.

Cell death & disease·2015
Same author

Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study.

Parkinsonism & related disorders·2015
Same author

Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.

International journal of immunopathology and pharmacology·2014
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Treatment for early Parkinson's disease (PD) varies by age. Younger patients prioritize symptom control and delaying levodopa, while older patients focus on functional improvement and avoiding cognitive side effects.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Parkinson's disease (PD) diagnosis requires careful consideration of medication options.
  • Individualized treatment plans are essential for managing PD symptoms and long-term outcomes.

Purpose of the Study:

  • To outline age-specific medication strategies for early Parkinson's disease.
  • To guide clinicians in selecting antiparkinsonian drugs based on patient age and treatment goals.

Main Methods:

  • Review of current treatment guidelines for early Parkinson's disease.
  • Analysis of medication efficacy and side effect profiles in different age groups.

Main Results:

  • For patients under 50, initial options include selegiline, amantadine, and anticholinergics.

Related Experiment Videos

  • For patients in their fifties, dopamine agonists may be added, followed by sustained-release carbidopa-levodopa.
  • For patients 60 and over, sustained-release carbidopa-levodopa is first-line, with caution regarding cognitive effects.

    • Conclusions:

    • Age-based treatment stratification is crucial for optimizing Parkinson's disease management.
    • Medication choices should balance symptom control, levodopa sparing, and minimizing adverse effects like cognitive impairment.